2018 surveillance (exceptional review) of low back pain and sciatica in over 16s: assessment and management (NICE guideline NG59)

Surveillance report Published: 31 October 2018

www.nice.org.uk

2018 surveillance (exceptional review) of low back pain and sciatica in over 16s: assessment and management (NICE guideline NG59)

Contents

Surveillance decision	3
Reasons for the decision	3
Other clinical areas	5
Equalities	5
Overall decision	5
How we made the decision	6
Evidence	6
Views of topic experts	6
Views of stakeholders	6
NICE Surveillance programme project team	6

Surveillance decision

We will not update the guideline on low back pain and sciatica in over 16s: assessment and management.

Reasons for the decision

Assessing the evidence

The purpose of this exceptional review was to examine the effectiveness of spinal fusion as a management option for low back pain and sciatica. NICE guideline NG59 currently states do not offer spinal fusion for people with low back pain unless as part of a randomised controlled trial (RCT). All other areas covered in the guideline scope were not considered by this exceptional review.

We decided to undertake an exceptional review of this area following publication of NICE's interventional procedures guidance on <u>transaxial interbody lumbosacral fusion for severe</u> <u>chronic low back pain</u> (IPG620). The recommendations in this interventional procedures guidance state that the evidence on efficacy is adequate in quality and quantity and this procedure may be used provided that standard arrangements are in place for clinical governance, consent and audit. There is also related NICE interventional procedures guidance on <u>lateral interbody fusion in the lumbar spine for low back pain</u> (IPG574) that is recommended for use. Because the populations in NICE guideline NG59 and NICE interventional procedures guidance 574 and 620 overlap, and the procedures covered (transaxial interbody lumbosacral fusion and lateral interbody fusion) are forms of spinal fusion (an intervention considered in NICE guideline NG59), we decided to review the area again and consider the impact on NICE's guideline on low back pain and sciatica.

See <u>appendix A</u>: summary of evidence from surveillance for details of all evidence considered, and references.

Guideline development

Transaxial interbody lumbosacral fusion and lateral interbody fusion were excluded from the scope of NICE guideline NG59 because they are covered in NICE interventional procedures guidance. However, the guideline did consider the clinical and cost effectiveness of spinal fusion in people with non-specific low back pain. Overall the guideline committee considered that there was no consistent benefit of spinal fusion over comparator treatments and evidence of potential harm. Given this and the limited number of studies from which data could be evaluated, the committee agreed that there was a lack of evidence of clinical effectiveness to recommend spinal fusion for people with low back pain other than in the context of a RCT.

Views of topic experts

We sent questionnaires to 5 topic experts and received 2 responses. The topic experts either:

- participated in the guideline committee who developed the guideline or
- were recruited to the NICE Centre for Guidelines Expert Advisers Panel to represent their specialty.

The responses from the topic experts suggested that the recommendation on spinal fusion in NICE guideline NG59 did not need to be updated and no further relevant new evidence was highlighted.

Impact

To develop NICE's interventional procedures recommendation on transaxial interbody lumbosacral fusion, the committee considered 2 systematic reviews, 1 non-randomised comparative study, 3 case series and 2 case reports. Most studies were retrospective, none were UK based and there was a lack of long term data. The only comparative data that was discussed by the Interventional Procedures Advisory Committee compared transaxial interbody lumbosacral fusion with other approaches for spinal fusion. The scope of the interventional procedure focused on severe, lifestyle limiting, chronic low back pain that has not responded to conservative treatment. In terms of lateral interbody fusion, the interventional procedures recommendation was based on 3 systematic reviews, 1 RCT, 2 non-RCTs, 3 case series and 6 case reports.

As interventional procedures focus on safety and efficacy of an intervention, we considered new evidence to determine the clinical and cost effectiveness of the procedure. No evidence directly assessing the effectiveness of transaxial interbody lumbosacral fusion or lateral interbody fusion for low back pain was identified, therefore

studies focusing on conventional spinal fusion were considered. The effectiveness of spinal fusion appears inconclusive from the results of the new evidence. There is some indication that spinal fusion shows similar clinical outcomes to other surgical procedures for patient reported pain and disability. However, the studies also highlight increased risks of safety and complications associated with spinal fusion. There is also a lack of data in the new evidence on the effectiveness of individual types of spinal fusion and there is a limited number of comparisons with other types of intervention. The new evidence is unlikely to affect the recommendation in NICE guideline NG59 which advises not to offer spinal fusion for people with low back pain unless as part of a RCT.

After taking into account the evidence base and views of topic experts, we acknowledge that this is an area of research showing promising results for some outcomes. However, the findings from this exceptional review have demonstrated a lack of data on the clinical and cost effectiveness of transaxial interbody lumbosacral fusion or lateral interbody fusion whilst the effectiveness of spinal fusion remains inconclusive and there is still uncertainty around the safety and risk of complications in this population. For this reason, we will not update the guideline at this time.

Other clinical areas

This exceptional surveillance review did not search for new evidence relating to other clinical areas in the guideline.

Equalities

No equalities issues were identified during the surveillance process.

Overall decision

After considering all evidence and other intelligence and the impact on current recommendations, we decided that no update is necessary at this time.

See how we made the decision for further information.

How we made the decision

Exceptionally, significant new evidence may mean an update of a guideline is agreed before the next scheduled check of the need for an update. The evidence might be a single piece of evidence, an accumulation of evidence or other published NICE guidance.

For details of the process and update decisions that are available, see <u>ensuring that</u> <u>published guidelines are current and accurate</u> in developing NICE guidelines: the manual.

Evidence

This exceptional review provides an overview of evidence relating to the use of spinal fusion for low back pain or sciatica published since the end of the search period for the guideline (December 2015). New evidence was considered in detail alongside topic expert feedback on the intervention to determine if there is an impact on the guideline.

Views of topic experts

We engaged with topic experts who were also members of the guideline committee involved in the development of NICE guideline NG59.

Views of stakeholders

Because this was an exceptional surveillance review we did not consult on the decision.

NICE Surveillance programme project team

Kay Nolan Associate Director

Janusz Jankowski Consultant Clinical Adviser

Emma McFarlane Technical Adviser 2018 surveillance (exceptional review) of low back pain and sciatica in over 16s: assessment and management (NICE guideline NG59)

Omar Moreea

Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-3101-9